Related Experiment Video
Updated: Feb 13, 2026

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
[Inhibitory effect and mechanism of platycodin D combined with imatinib on K562/R]
1First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China.
Abstract:
Platycodin D(PD) has a significantly inhibitory effect on multiple malignant tumors, and can inhibit the proliferation of leukemia cells K562 and induce apoptosis. However, its effect in improving the sensitivity of drug-resistant cells to imatinib and their molecular mechanism remained unclear. To investigate the effect and mechanism of PD alone or combined with imatinib (IM) in inhibiting CML imatinib resistant cell line K562/R, the cell proliferation was examined by CCK8 assay to reveal the effect of PD on the inhibitory function of imatinib. Cell apoptosis was detected by Annexin V-FITC/PI double staining. Protein expressions of cleaved caspase-3, cleaved caspase-9, PARP, cleaved PARP, Bcr/abl, p-AKT and p-mTOR were detected by Western blot. The results showed that the inhibitory effect of PD combined with imatinib on the proliferation and apoptosis of K562/R cells was significantly higher than that of the control group and the single drug group. Protein expressions of cleaved caspase-3, cleaved caspase-9 and cleaved PARP were significantly up-regulated in the combination group, and protein expressions of PARP, Bcr/abl, p-AKT and p-mTOR were down-regulated. The results indicated that PD increased the sensitivity of drug-resistant cells to imatinib, and the inhibitory effect of PD combined with imatinib was significantly better than the single drug on cell proliferation, induction of apoptosis, inhibition of Bcr/abl protein and PI3K/AKT/mTOR signaling pathway.
Insights
Platycodin D enhances imatinib sensitivity in resistant leukemia cells. Combining Platycodin D with imatinib significantly inhibits proliferation and induces apoptosis by targeting key proteins and signaling pathways.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- Platycodin D (PD) shows promise against various cancers, including leukemia.
- Imatinib (IM) is a standard treatment for chronic myeloid leukemia (CML), but resistance is a challenge.
- The mechanism by which PD affects imatinib-resistant cells remains largely unknown.
Purpose of the Study:
- To investigate the efficacy of Platycodin D, alone or combined with imatinib, against imatinib-resistant K562/R leukemia cells.
- To elucidate the molecular mechanisms underlying the combined treatment's effects on drug-resistant CML cells.
Main Methods:
- Cell proliferation was assessed using the CCK8 assay.
- Apoptosis was detected via Annexin V-FITC/PI double staining.
- Western blotting was employed to analyze protein expression levels of key apoptotic and signaling molecules (cleaved caspase-3, cleaved caspase-9, PARP, Bcr/abl, p-AKT, p-mTOR).
Main Results:
- The combination of PD and imatinib demonstrated a significantly greater inhibitory effect on K562/R cell proliferation and apoptosis compared to single-agent treatments.
- Combined therapy led to increased expression of cleaved caspase-3, cleaved caspase-9, and cleaved PARP.
- PD and imatinib combination downregulated PARP, Bcr/abl, p-AKT, and p-mTOR protein levels.
Conclusions:
- Platycodin D effectively resensitizes imatinib-resistant leukemia cells to imatinib.
- The combination therapy shows superior efficacy in inhibiting proliferation and inducing apoptosis.
- The observed effects are mediated through the modulation of Bcr/abl protein expression and the PI3K/AKT/mTOR signaling pathway.
More Related Videos
Related Concept Videos
Excitatory and Inhibitory Effects of Neurotransmitters
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Mechanical Protein Functions
Combining Functions
Impedance Combination
Combination Of Resistors

